SG11201701711VA - Anti-glucagon antibodies and uses thereof - Google Patents

Anti-glucagon antibodies and uses thereof

Info

Publication number
SG11201701711VA
SG11201701711VA SG11201701711VA SG11201701711VA SG11201701711VA SG 11201701711V A SG11201701711V A SG 11201701711VA SG 11201701711V A SG11201701711V A SG 11201701711VA SG 11201701711V A SG11201701711V A SG 11201701711VA SG 11201701711V A SG11201701711V A SG 11201701711VA
Authority
SG
Singapore
Prior art keywords
glucagon antibodies
glucagon
antibodies
Prior art date
Application number
SG11201701711VA
Inventor
Haruka Okamoto
Jesper Gromada
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201701711VA publication Critical patent/SG11201701711VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
SG11201701711VA 2014-09-16 2015-09-15 Anti-glucagon antibodies and uses thereof SG11201701711VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050889P 2014-09-16 2014-09-16
PCT/US2015/050281 WO2016044337A1 (en) 2014-09-16 2015-09-15 Anti-glucagon antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201701711VA true SG11201701711VA (en) 2017-04-27

Family

ID=54197130

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701711VA SG11201701711VA (en) 2014-09-16 2015-09-15 Anti-glucagon antibodies and uses thereof

Country Status (16)

Country Link
US (2) US9657099B2 (en)
EP (1) EP3194441A1 (en)
JP (1) JP2017533695A (en)
KR (1) KR20170062466A (en)
CN (1) CN107001461A (en)
AU (1) AU2015317899A1 (en)
BR (1) BR112017005110A2 (en)
CA (1) CA2960763A1 (en)
CL (1) CL2017000651A1 (en)
CO (1) CO2017002719A2 (en)
EA (1) EA201790377A1 (en)
IL (1) IL251000A0 (en)
MX (1) MX2017003535A (en)
PH (1) PH12017500402A1 (en)
SG (1) SG11201701711VA (en)
WO (1) WO2016044337A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
TW202340452A (en) 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
CA3026521A1 (en) * 2016-06-27 2018-01-04 President And Fellows Of Harvard College Compounds useful to treat metabolic disorders
CN107586336A (en) * 2016-07-09 2018-01-16 复旦大学 For the full human monoclonal antibody of zika virus and application
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX2019002437A (en) * 2016-08-30 2019-10-09 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling.
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
RU2019126781A (en) 2017-01-27 2021-03-01 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. PROTEINS BINDING GLUCAGON RECEPTORS AND METHODS OF THEIR APPLICATION
WO2018227200A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
WO2019152303A1 (en) 2018-01-31 2019-08-08 Regeneron Pharmaceuticals, Inc. Systems and methods for characterizing drug product impurities
TWI786265B (en) 2018-02-02 2022-12-11 美商再生元醫藥公司 System and method for characterizing protein dimerization
BR112020013426A2 (en) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. methods for identifying a virus in a sample and for detecting viral nucleic acids in a cell culture sample
KR20200129108A (en) * 2018-03-08 2020-11-17 페인스 테라퓨틱스 인코포레이티드 Anti-TIP-1 antibodies and uses thereof
FI3768709T3 (en) 2018-03-19 2024-02-01 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
TW202016125A (en) 2018-05-10 2020-05-01 美商再生元醫藥公司 Systems and methods for quantifying and modifying protein viscosity
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
AU2019329686A1 (en) 2018-08-27 2020-12-03 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
BR112020026348A2 (en) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. METHOD FOR ASSESSING STEQUIOMETRY AND SIZE DISTRIBUTION OF PROTEIN COMPLEXES, FOR SELECTING A MAIN PROTEIN MEDICINE AND FOR CHARACTERIZING PROTEIN COMPLEXES, AND PHARMACEUTICAL COMPOSITION
EP3857236A1 (en) 2019-01-16 2021-08-04 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
KR20220066393A (en) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. Systems and methods for the use and regeneration of chromatography
EP4065086A1 (en) 2019-11-25 2022-10-05 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
IL294765B2 (en) 2020-01-21 2023-12-01 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
TW202227473A (en) * 2020-10-23 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 Glp1-gcgr antibody fusion protein variants and the composition thereof
US20220160828A1 (en) 2020-11-25 2022-05-26 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CA3205135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
WO2022159437A1 (en) * 2021-01-20 2022-07-28 Eli Lilly And Company Oxyntomodulin binding molecules, and uses thereof
JP2024503408A (en) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド How to improve protein titer in cell culture
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
IL305731A (en) 2021-03-26 2023-11-01 Regeneron Pharma Methods and systems for developing mixing protocols
IL308864A (en) 2021-06-01 2024-01-01 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
AR127006A1 (en) 2021-09-08 2023-12-06 Regeneron Pharma A HIGH-PERFORMANCE, MASS SPECTROMETRY-BASED METHOD FOR QUANTIFYING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
TW202328179A (en) 2021-09-20 2023-07-16 美商再生元醫藥公司 Methods of controlling antibody heterogeneity
TW202323817A (en) 2021-10-07 2023-06-16 美商再生元醫藥公司 Systems and methods of ph modeling and control
TW202331252A (en) 2021-10-07 2023-08-01 美商再生元醫藥公司 Ph meter calibration and correction
TW202330104A (en) 2021-10-26 2023-08-01 美商再生元醫藥公司 Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN114410590B (en) * 2022-01-27 2024-01-09 广州市进德生物科技有限公司 Glucagon-secreting monoclonal antibody hybridoma cell strain, monoclonal antibody and application thereof
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (en) 1977-02-10 1983-08-08 大塚製薬株式会社 Antibody production method
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
JP2729159B2 (en) 1994-10-31 1998-03-18 日清製粉株式会社 Monoclonal antibody of human glicentin, hybridoma producing the antibody, and method for quantifying human glicentin using the same
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070173473A1 (en) 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2649751A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
US20090326041A1 (en) 2006-05-05 2009-12-31 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
ATE537190T1 (en) 2006-06-02 2011-12-15 Regeneron Pharma HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR
CN101636179B (en) 2006-11-07 2012-10-10 默沙东公司 Antagonists of pcsk9
US20100040610A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
US20100040611A1 (en) 2006-11-07 2010-02-18 Sparrow Carl P Antagonists of pcsk9
WO2008057458A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JP2010523135A (en) 2007-04-13 2010-07-15 ノバルティス アーゲー Molecules and methods for preparing proprotein convertase subtilisin / kexin type 9 (PCSK9)
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
KR20100017169A (en) 2007-05-22 2010-02-16 노파르티스 아게 Methods of treating, diagnosing and detecting fgf21-associated disorders
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
MX2010004454A (en) 2007-10-26 2010-07-28 Schering Corp Anti-pcsk9 and methods for treating lipid and cholesterol disorders.
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US20110065644A1 (en) 2008-03-09 2011-03-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
KR20120056800A (en) * 2009-09-08 2012-06-04 (주)네오팜 Antibodies against glucagon receptor and their use
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
JO3756B1 (en) 2010-11-23 2021-01-31 Regeneron Pharma Human antibodies to the glucagon receptor
WO2013081993A1 (en) 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains

Also Published As

Publication number Publication date
CL2017000651A1 (en) 2017-12-15
WO2016044337A1 (en) 2016-03-24
US20160075778A1 (en) 2016-03-17
US20170218065A1 (en) 2017-08-03
JP2017533695A (en) 2017-11-16
BR112017005110A2 (en) 2018-01-23
CN107001461A (en) 2017-08-01
CO2017002719A2 (en) 2017-06-20
MX2017003535A (en) 2017-10-27
KR20170062466A (en) 2017-06-07
PH12017500402A1 (en) 2017-07-17
EP3194441A1 (en) 2017-07-26
CA2960763A1 (en) 2016-03-24
IL251000A0 (en) 2017-04-30
AU2015317899A1 (en) 2017-04-06
US9657099B2 (en) 2017-05-23
EA201790377A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
IL251000A0 (en) Anti-glucagon antibodies and uses thereof
HK1255067A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en) Anti-interleukin-33 antibodies and uses thereof
HK1254861A1 (en) Anti-lag3 antibodies and uses thereof
HK1245154A1 (en) Anti-cd47 antibodies and uses thereof
HK1252615A1 (en) Il-8-binding antibodies and uses thereof
HK1249911A1 (en) Anti-muc16 antibodies and uses thereof
HK1243940A1 (en) Anti-pro/latent-myostatin antibodies and uses thereof
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
HK1256381A1 (en) Anti-pacap antibodies and uses thereof
IL251837A0 (en) Anti-endoglin antibodies and uses thereof
IL247315B (en) Anti-acth antibodies and use thereof
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
HK1254240A1 (en) Anti-hypusine antibodies and uses thereof